Clinical trial · no report yet · Phase 3
QuANTUM-WILD
Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML
- NCT06578247 ↗
- Active not recruiting
- Daiichi Sankyo
- 18 commentary sources found
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| YouTube | 13 | |
| Podcasts | 5 |
The trial
ClinicalTrials.gov- Official title
- A Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial Of Quizartinib Administered in Combination With Induction and Consolidation Chemotherapy and Administered as Maintenance Therapy in Adult Patients With Newly Diagnosed FLT3-ITD Negative Acute Myeloid Leukemia
- Phase
- Phase 3
- Status
- Active not recruiting
- Conditions
- Leukemia
- Interventions
- Quizartinib; Placebo; Chemotherapy
- Arms
- Arm A: Quizartinib + Chemotherapy · Experimental
- Arm B: Placebo + Chemotherapy · Placebo comparator
- Arm C: Quizartinib + Chemotherapy then Placebo Maintenance · Experimental
- Enrollment
- 700 (estimated)
- Primary outcomes
- Overall Survival (Arm A vs Arm B)
- Sponsor
- Daiichi Sankyo
- Start
- Nov 19, 2024
- Primary completion
- Jun 26, 2030 (estimated)
- Results posted
- No
- Registry record
- NCT06578247 · updated Jul 2, 2026
Publications
linked from the registry- Montesinos P, Altman JK, Bullinger L, Cheong JW, Fathi AT, Levis MJ, Luger S, Miyamoto T, Oliva EN, Perl AE, Recher C, Veiga RR, Wang J, Zeidan AM, Liu L, Duong Y, Rohrbach JEC, Inghirami G, Alexis K, Gosberg A, Nahar A, Burns K, Daver N, Erba HP. QuANTUM-Wild: a Phase III, randomized trial of quizartinib in newly diagnosed FLT3-ITD-negative acute myeloid leukemia. Future Oncol. 2026 Jul;22(16):1913-1924. doi: 10.1080/14796694.2026.2689464. Epub 2026 Jul 11. PubMed 42434847